

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

Complete if Known

Application Number 09/804,690
Filing Date March 12, 2001
First Named Inventor COHEN, STANLEY N.
Group Art Unit 1642
Examiner Name YU, MISOOK
Attorney Docket Number STAN-010CON

RECEIVED

JAN 02 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁸
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
my		WO	93/07266	A	Guerra et al.	04-15-1993		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
my		SKARNES, W.C., (1993), <i>Curr. Opin. Biotech.</i> , 4:684-689	
		SKARNES, W.C. et al., (1992), <i>Genes and Dev.</i> , 6(6):903-918	
		ERICKSON, R.P. et al., (1993), <i>Developmental Genetics</i> , 4(14):274-281	
		WAYNE DAVIES, R et al., (1994), <i>Prog. Neurobiol.</i> , 2(42):319-331	
		EMBL Database Accession no: x82319, 27 April 1995	
		EMBL Database Accession no: u52945, 28 May 1996	

Examiner Signature	<i>Misook Yu</i>	Date Considered	<i>Misook Yu</i>
--------------------	------------------	-----------------	------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

(Use several sheets if necessary)

ATTY. DOCKET NO.
STAN010CON

SERIAL NO. 09/804,690

Confirmation No. 1876

APPLICANT

Cohen et al.

FILING DATE

March 12, 2001

GROUP

1645

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
my	AA	5,892,016	04/06/1999	Brie et al.		

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

my	AB	Baim, et al., "A Chimeric Mammalian Transactivator Based On The <i>lac</i> Repressor That IS Regulated By Temperature And Isopropyl β -D-Thiogalactopyranoside," <i>PNAS USA</i> (1991) Vol. 88:5072-5076.
	AC	Baubonis and Sauer, "Genomic Targeting With Purified Cre Recombinase," <i>Nucleic Acids Research</i> (1993) Vol. 21:2025-2029.
	AD	Craig, "The Mechanism of Conservative Site-Specific Recombination," <i>Annu. Rev. Genet.</i> (1988) Vol. 22:77-105.
	AE	Dowdy, et al., <i>Science</i> (1991) Vol. 254:293-295.
	AF	Ferti-Passantonopoulou, et al., "Preferential Involvement of 11q23-24 and 11p15 in Breast Cancer," <i>Cancer Genet Cytogenet</i> (1991) Vol. 51:183-188.
	AG	Gabra, et al., "Chromosome 11 Allele Imbalance and Clinicopathological Correlates in Ovarian Tumours," <i>British Journal of Cancer</i> (1995) Vol. 72:367-375.
	AH	Giese, et al., "Mouse P. Gene Disruption Leads to Hypomyelination, Abnormal Expression of Recognition Molecules, and Degeneration of Myelin and Axons," <i>Cell</i> (1992) Vol. 71:565-576.
	AI	Gossen, et al., "Transcriptional Activation by Tetracyclines in Mammalian Cells," <i>Science</i> (1995) Vol. 268:1766-1769.
	AJ	Kallioniemi, et al., "Identification of Gains and Losses of DNA Sequence in Primary Bladder Cancer by Comparative Genomic Hybridization," <i>Genes, Chromosomes & Cancer</i> (1995) Vol. 12:213-219.
	AK	Kamano, et al., "Effects of the Antisense v-myb Expression on K562 Human Leukemia Cell Proliferation and Differentiation," <i>Leukemia Research</i> (1990) Vol. 14:831-839.
	AL	Katsuki, et al., "Conversion of Normal Behavior to Shiverer by Myelin Basic Protein Antisense cDNA in Transgenic Mice," <i>Reports</i> (1988) Vol. 241:593-595.
	AM	Lemke, "The Molecular Genetics of Myelination: An Update," <i>GLIA</i> (1993) Vol. 7:263-271.
	AN	Maucer, et al., "Stathmin Interaction With a Putative Kinase and Coiled-Coil-Forming Protein Domains," <i>Proc. Natl. Acad. Sci. USA</i> (1995) Vol. 92:3100-3104.
	AO	Miki, et al., <i>Science</i> (1994) Vol. 266:66-71.
	AP	Mullokandov, et al., "Genomic Alterations in Cervical Carcinoma: Losses of Chromosome Heterozygosity and Human Papilloma Virus Tumor Status," <i>Cancer Research</i> (1996) Vol. 56:197-205.


EXAMINER

misroch y


DATE CONSIDERED

6-4-03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) (Use several sheets if necessary)		ATTY. DOCKET NO. STAN010CON	SERIAL NO. 09/804,690 Confirmation No. 1876
		APPLICANT Cohen et al.	
		FILING DATE March 12, 2001	GROUP 1645
	AQ Owens and Boyd, "Expressing Antisense Po RNA in Schwan Cells Perturbs Myelination," <i>Development</i> (1991) Vol. 112:639-649.		
	AR Owens and Bunge, "Schwann Cells Infected With a Recombinant Retrovirus Expressing Myelin-Associated Glycoprotein Antisense RNA Do Not Form Myelin," <i>Neuron</i> (1991) Vol. 7:565-575.		
	AS Sobel, <i>Trends. Biochem. Sci.</i> (1991) Vol. 16:301-305.		
	AT Stokes, et al., "The Partial 3' Conserved Segment Duplications in the Inegrons In6 from pSa and In7 from pDG0100 Have a Common Origin," <i>Plasmid</i> (1993) Vol. 30:39-50.		
	AU Voorter, et al., "Loss of Chromosomes 11 and 11 P/Q Imbalances in Bladder Cancer Detected by Fluorescence in situ Hybridization," <i>Int. J. Cancer</i> (1996) Vol. 65:301-307		
	AV Wooster, et al., <i>Nature</i> (1995) Vol.378:789-792.		
	AW Genbank Accession Number H53754, Alignment Against Human TSG 101 Sequence		
✓	AX Genbank Accession Number 230135, Alignment Against Human TSG 101 Sequence		

F:\forms\word 2k forms\form PTO-1449.doc

EXAMINER 	DATE CONSIDERED 6-4-03
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)


Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known		
				Application Number	09/804,690	
Sheet		1	of	1	Filing Date	March 12, 2001
					First Named Inventor	Cohen
					Group Art Unit	1642
					Examiner Name	To Be Assigned
					Attorney Docket Number	STAN-010CON

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		6,274,312		Gish et al.	08-14-2001	



RECEIVED
NOV 15 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

Examiner Signature	<i>M. Cohen</i>	Date Considered	6-4-03
-----------------------	-----------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.